| Authors: |
Lauer UM; Department of Internal Medicine VIII, Medical Oncology & Pneumology, University Hospital Tübingen, Tübingen, Germany; German Cancer Research Center (DKFZ), Member of the German Cancer Consortium (DKTK), Tübingen, Germany. Electronic address: ulrich.lauer@uni-tuebingen.de., Awada A; Oncology Medicine Department, Jules Bordet Institute, Brussels, Belgium., Postel-Vinay S; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; INSERM Unit U981, Gustave Roussy, Villejuif, France; University College of London Cancer Institute, London, UK., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Thieblemont C; Université Paris Cité & Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Hémato-oncologie, Paris, France., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, USA., Paik PK; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Shepard DR; Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, USA., Docampo LI; Lung and Head and Neck Cancer Unit, Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Galot R; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Rottey S; Drug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium., Sadrolhefazi B; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, USA., Marzin K; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany., Musa H; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. |
